the First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230000, China
Location status: Recruiting
NCT Number: NCT07782684
The primary objective is to investigate the correlation between specific patterns of γδ T cell reconstitution after umbilical cord blood transplantation and key clinical outcomes.
Interested in participating?
Request InfoAll sexes
Observational
Hefei, Anhui, 230000, China
Location status: Recruiting
This study is a prospective, observational clinical investigation. Allogeneic umbilical cord blood transplantation is a critical treatment for hematological malignancies and other disorders. However, the reconstitution of the immune system post-transplantation, particularly the dynamics of non-conventional γδ T cells compared to αβ T cells, and their impact on clinical outcomes remain poorly understood.
This study aims to systematically characterize the reconstitution kinetics of γδ T cells and their subsets in patients following allogeneic UCBT. We will sequentially collect peripheral blood samples from patients post-transplant and dynamically monitor the quantity, proportion, and changes in major functional subsets of γδ T cells using flow cytometry.
The primary objective is to investigate the correlation between specific patterns of γδ T cell reconstitution and key clinical outcomes. These outcomes include the incidence and severity of graft-versus-host disease, disease relapse rate, transplant-related mortality, and overall patient survival. We anticipate that this study will identify novel biomarkers for assessing immune reconstitution status after UCBT and provide a rationale for future immunotherapeutic strategies aimed at modulating γδ T cells to improve patient prognosis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
2: Diagnosis of a hematologic malignancy or disorder eligible for UCBT (e.g., acute leukemia, myelodysplastic syndrome, severe aplastic anemia)
3: Willing and able to provide written informed consent.
4: No restrictions on gender, age, or race.
Exclusion criteria
Allogeneic umbilical cord blood transplantation as a standard treatment for underlying hematological diseases.
Time frame: 1 year
The reconstitution level of γδ T cells in peripheral blood will be measured by flow cytometry at 1, 2, 3, 6, 9, and 12 months after umbilical cord blood transplantation. The outcome is measured as the absolute cell count per microliter of blood and/or the percentage of γδ T cells within total lymphocytes.
Time frame: 1-5 year
Overall survival is defined as the time from the date of umbilical cord blood transplantation to the date of death from any cause. Patients who are still alive at the time of analysis will be censored at the last known date of contact.
Time frame: 1-5 year
Leukemia-free survival is defined as the time from transplantation to the first event of either relapse or death from any cause. Patients who are alive and relapse-free at the time of analysis will be censored at the last follow-up date.
Time frame: 1-2 year
GRFS is defined as the time from transplantation to the first event of grade III-IV acute GVHD, chronic GVHD requiring systemic treatment, relapse, or death from any cause.
Time frame: 1-5 year
The cumulative incidence of disease relapse will be calculated, considering death without relapse as a competing risk.
Time frame: 100 days, 1-2 year
The incidence and severity of grades II-IV and III-IV acute GVHD will be assessed and graded according to the Mount Sinai Acute GVHD International Consortium (MAGIC) criteria or the classic Glucksberg criteria. The incidence and severity of chronic GVHD will be assessed and graded according to the National Institutes of Health (NIH) consensus criteria.
Contact information is provided by the study sponsor or research team.
Xiao yu Zhu, ph.D
CONTACT
Xing chi Chen
CONTACT
Anhui Provincial Hospital
Other Gov
Reconstruction Kinetics of γδ T Cells and Their Clinical Impact After Unrelated Cord Blood Transplantation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07075185
Blood Protein Disorders, Cardiovascular Diseases
Duarte, California, United States
View Trial DetailsNCT07313059
CCUS Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis
Canberra, Australian Capital Territory, Australia
View Trial DetailsNCT06828796
Disease, Hematologic Disease and Disorders
Atlanta, Georgia, United States
View Trial DetailsNCT00001620
Agranulocytosis, Anemia
Bethesda, Maryland, United States
View Trial Details